Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Verbrugge, Ellen ^a   Scheper, Rik J ^a   Lems, Willem F ^a   de Gruijl, Tanja D ^a   Jansen, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; CD20 ANTIGEN; DELANZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; IXAZOMIB CITRATE; ONX 0914; OPROZOMIB; PR 924; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EFFECTOR CELL; GENE REPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; LONG TERM CARE; MACROPHAGE; MACROPHAGE FUNCTION; METABOLIC CAPACITY; MONOCYTE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CELL; POLYNEUROPATHY; REVIEW; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTOPENIA; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84924340276     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0529-1     Document Type: Review

References (61)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146:406-15.
3. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2014;73:871-82.
4. Fierabracci A. Proteasome inhibitors: a new perspective for treating autoimmune diseases. Curr Drug Targets. 2012;13:1665-75.
5. Basler M, Kirk CJ, Groettrup M. The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol. 2012;25:74-80.
6. Moran E, Carbone F, Augusti V, Patrone F, Ballestrero A, Nencioni A. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol. 2012;49:270-6.
7. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol. 2012;19:99-115.
8. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell. 2010;142:613-24.
9. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A. 2010;107:18599-604.
10. Murata S, Yashiroda H, Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol. 2009;10:104-15.
11. Egerer T, Martinez-Gamboa L, Dankof A, Stuhlmüller B, Dörner T, Krenn V, et al. Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome. Arthritis Rheum. 2006;54:1501-8.
12. Scheffler S, Kuckelkorn U, Egerer K, Dörner T, Reiter K, Soza A, et al. Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i). Rheumatology. 2008;47:622-6.
13. Zaiss DMW, Bekker CPJ, Gröne A, Lie BA, Sijts AJ. Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol. 2011;187:2302-9.
14. Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC, et al. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol. 2012;13:129-35.
15. Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest. 2011;121:4150-60.
16. Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell. 2013;152:1184-94.
17. Egerer K, Kuckelkorn U, Rudolph PE, Rückert JC, Dörner T, Burmester GR, et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol. 2002;29:2045-52.
18. Sixt SU, Dahlmann B. Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta. 2008;1782:817-23.
19. Morawietz L, Martinez-Gamboa L, Scheffler S, Hausdorf G, Dankof A, Kuckelkorn U, et al. Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome. J Rheumatol. 2009;36:2694-703.
20. Brychcy M, Kuckelkorn U, Hausdorf G, Egerer K, Kloetzel PM, Burmester GR, et al. Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28. Arthritis Rheum. 2006;54:2175-83.
21. Feist E, Dörner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, et al. Proteasome alpha-type C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med. 1996;184:1313-8.
22. Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol. 2012;199:583-8.
23. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947-59.
24. Huber EM, Groll M. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development. Angew Chem Int Ed Engl. 2012;51:8708-20.
25. Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, et al. Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst. 2010;102:1069-82.
26. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748-55.
27. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009;15:781-7.
28. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124:234-46.
29. Zinser E, Rössner S, Littmann L, Lüftenegger D, Schubert U, Steinkasserer A. Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology. 2009;214:843-51.
30. Meister S, Schubert U, Neubert K, Burger R, Gramatzki M, Hahn S, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783-92.
31. Obeng E, Carlson L, Gutman D, Harrington WJ, Lee K, Boise L. Proteasome inhibitors induce a terminal unfolded response in multiple myeloma cells. Blood. 2006;107:4907-16.
32. Bianchi G, Oliva L, Gascio P, Pengo N, Fontana F, Cerruti F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113:3040-9.
33. Qureshi AA, Tan X, Reis JC, Badr MZ, Papasian CJ, Morrison DC, et al. Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids Heal Dis. 2011;10:177.
34. Yannaki E, Papadopoulou A, Athanasiou E, Kaloyannidis P, Paraskeva A, Bougiouklis D, et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum. 2010;62:3277-88.
35. Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH, et al. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum. 2011;63:670-80.
36. Pernis A. Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med. 2009;265:644-52.
37. Van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BAC, Jansen G. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol. 2009;27:92-8.
38. Kalim KW, Basler M, Kirk CJ, Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol. 2012;189:4182-93.
39. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41-52.
40. Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dörken B, et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol. 2007;68:147-55.
41. Hirai M, Kadowaki N, Kitawaki T, Fujita H, Takaori-Kondo A, Fukui R, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood. 2011;117:500-9.
42. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64:493-503.
43. Dörner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 2010;125:464-75.
44. Drake L, McGovern-Brindisi EM, Drake JR. BCR ubiquitination controls BCR-mediated antigen processing and presentation. Blood. 2006;108:4086-93.
45. Van Anken E, Romijn EP, Maggioni C, Mezghrani A, Sitia R, Braakman I, et al. Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity. 2003;18:243-53.
46. Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25:1104-13.
47. Gomez AM, Vrolix K, Martinez-Martinez P, Molenaar PC, Phernambucq M, van der Esch E, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol. 2011;186:2503-13.
48. Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, et al. Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol. 2013;2:2.
49. Van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pr Rheumatol. 2007;3:26-34.
50. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24:306-11.
51. Kale AJ, Moore BS. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem. 2012;55:10317-27.
52. Martinez-Gamboa L, Lesemann K, Kuckelkorn U, Scheffler S, Ghannam K, Hahne M, et al. Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome. J Rheumatol. 2013;40:663-73.
53. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, et al. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 2012;26:757-68.
54. Verbrugge SE, Assaraf YG, Dijkmans BAC, Scheffer GL, Al M, den Uyl D, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther. 2012;341:174-82.
55. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489-99.
56. Van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, et al. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol. 2009;86:1075-87.
57. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63:6174-7.
58. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120:3260-70.
59. Hiepe F, Alexander T, Peukert R, Rubbert A, Rech J, Braun T, et al. Refractory SLE patients respond to the proteasome inhibitor bortezomib. Ann Rheum Dis. 2012;71:A15-6.
60. ClinicalTrials.gov. Velcade for Proliferative Lupus Nephritis [ http://clinicaltrials.gov/ct2/show/NCT01169857?term=bortezomib%2Bautoimmune%2Bdisease&rank=4 ]
61. Arastu-Kapur S, Anderl J, Kraus M, Parlati F, Shenk K, Lee S, et al. Nonproteasomal targets of the proteasome inhibitor bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734-43.